Cited by 364Inflammatory Bowel DiseaseProbiotics and Fermented FoodsGut microbiota and health

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Effect of Probiotics on Inducing Remission and Maintaining Therapy in Ulcerative Colitis, Crohnʼs Disease, and Pouchitis: Meta-analysis of Randomized Controlled Trials

Shen, Jun, Zuo, Zhi-Xiang, Mao, Ai-Ping·2014·Inflammatory Bowel Diseases

Open this paper in CoChat — free account

Abstract

BACKGROUND: Whether probiotics are beneficial at all stages of treatment in inflammatory bowel disease or superior to placebo remains controversial. METHODS: Two reviewers independently selected randomized controlled trials comparing probiotics with controls in inflammatory bowel disease and extracted data related to remission/response rates, relapse rates, and adverse events. Subanalyses were also performed. RESULTS: Twenty-three randomized controlled trials with a total of 1763 participants met the inclusion criteria. From the meta-analysis, probiotics significantly increase the remission rates in patients with active ulcerative colitis (UC) (P = 0.01, risk ratio [RR] = 1.51). The remission rates were significantly higher in patients with active UC treated with probiotics than placebo (P < 0.0001, RR = 1.80). Unfortunately, subgroup analysis found that only VSL#3 significantly increased the remission rates compared with controls in patients with active UC (P = 0.004, RR = 1.74). Interestingly, VSL#3 (P < 0.00001, RR = 0.18) also significantly reduced the clinical relapse rates for maintaining remission in patients with pouchitis. No significantly different adverse events were detected between probiotics and controls in the treatment of UC (P = 0.94, RR = 0.99) or CD (P = 0.33, RR = 0.87). CONCLUSIONS: Administration of probiotics results in additional benefit in inducing remission of patients with UC. VSL#3 are beneficial for maintaining remission in patients with pouchitis. And, probiotics can provide the similar effect as 5-aminosalicylic acid on maintaining remission of UC, although no additional adverse events presented.

Integrity signals

Registry

Crossref · 10.1097/01.mib.0000437495.30052.be

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial
Gionchetti, P., Rizzello, F., Venturi, A., Brigidi, P., Matteuzzi, D., Bazzocchi, G., Poggioli, G., Miglioli, M., & Campieri, M. (2000) · Gastroenterology · doi:10.1053/gast.2000.9370 · Cited by 1,485
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial
Gionchetti, P., Rizzello, F., Helwig, U., Venturi, A., Lammers, K. M., Brigidi, P., Vitali, B., Poggioli, G., Miglioli, M., & Campieri, M. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00171-9 · Cited by 1,147
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial
Rembacken, B., Snelling, A. M., Hawkey, P. M., Chalmers, D. M., & Axon, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06343-0 · Cited by 1,100
Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics
Sartor, R. B. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.024 · Cited by 1,053
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis
Mimura, T., Rizzello, F., Helwig, U., Poggioli, G., Schreiber, S., Talbot, I. C., Nicholls, R. J., Gionchetti, P., Campieri, M., & Kamm, M. A. (2003) · Gut · doi:10.1136/gut.53.1.108 · Cited by 912
Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
Kruis, W., SCHÜTZ, E., Fric, P., Fixa, B., Judmaier, G., & Stolte, M. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.00225.x · Cited by 774
Synbiotic therapy ( Bifidobacterium longum /Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial
Furrie, E., Macfarlane, S., Kennedy, A., Cummings, J. H., Walsh, S. V., O’Neil, D. A., & Macfarlane, G. T. (2005) · Gut · doi:10.1136/gut.2004.044834 · Cited by 766
Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG
Prantera, C. (2002) · Gut · doi:10.1136/gut.51.3.405 · Cited by 566
Effect of a Probiotic Preparation (VSL#3) on Induction and Maintenance of Remission in Children With Ulcerative Colitis
Miele, E., Pascarella, F., Giannetti, E., Quaglietta, L., Baldassano, R. N., & Staiano, A. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.118 · Cited by 517
The Probiotic Preparation, VSL#3 Induces Remission in Patients With Mild-to-Moderately Active Ulcerative Colitis
Sood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.016 · Cited by 513
Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
Tursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., Forti, G., Morini, S., Hassan, C., Pistoia, M. A., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.218 · Cited by 489 · cited 3×
“38 , 4 pouchitis, 20, 22 , 25, 39 for”
BackgroundInfluential
Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis
Mennigen, R. B., Nolte, K., Rijcken, E. J. M., Utech, M., Loeffler, B., Senninger, N. J., & Bruewer, M. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90534.2008 · Cited by 484
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis
Zocco, M. A., Verme, L. Z. D., Cremonini, F., Piscaglia, A. C., Nista, E. C., Candelli, M., Novi, M., Rigante, D., Cazzato, I. A., Ojetti, V., et al. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02927.x · Cited by 472
Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial
Marteau, P. R., Lémann, M., Seksik, P., Laharie, D., Colombel, J. F., Bouhnik, Y., Cadiot, G., Soulé, J. C., Bourreille, A., Metman, E.-H., et al. (2005) · Gut · doi:10.1136/gut.2005.076604 · Cited by 412
Crohn's Disease and Escherichia coli
Malchow, H. A. (1997) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199712000-00021 · Cited by 402
Randomized placebo‐controlled trial assessing the effect of bifidobacteria‐fermented milk on active ulcerative colitis
Kato, K., Mizuno, S., Umesaki, Y., Ishii, Y., Sugitani, M., Imaoka, A., Otsuka, M., Hasunuma, O., Kurihara, R., Iwasaki, A., et al. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02268.x · Cited by 397
Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide
Fernandez, E. M., Valenti, V., Rockel, C., Hermann, C., Pot, B., Boneca, I. G., & Grangette, C. (2011) · Gut · doi:10.1136/gut.2010.232918 · Cited by 376
A Randomized, Double-blind Trial of Lactobacillus GG Versus Placebo in Addition to Standard Maintenance Therapy for Children with Crohnʼs Disease
Bousvaros, A., Guandalini, S., Baldassano, R. N., Botelho, C. A., Evans, J., Ferry, G. D., Goldin, B. R., Parker‐Hartigan, L., Kugathasan, S., Levy, J. F., et al. (2005) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000175905.00212.2c · Cited by 363
Lactobacillus GG in inducing and maintaining remission of Crohn's disease
Schultz, M., Timmer, A., Herfarth, H. H., Sartor, R. B., Vanderhoof, J. A., & Rath, H. C. (2004) · BMC Gastroenterology · doi:10.1186/1471-230x-4-5 · Cited by 349
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
Rutgeerts, P., Vermeire, S. A. R. A., & Assche, G. V. (2007) · Gut · doi:10.1136/gut.2005.088732 · Cited by 325
Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohnʼs disease after ileo-caecal resection
Gossum, A. V., Dewit, O., Louis, E. J., Hertogh, G., Baert, F., Fontaine, F., Devos, M., Enslen, M., Paintin, M., & Franchimont, D. P. (2006) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20063 · Cited by 296
Clinical trial: the microbiological and immunological effects of synbiotic consumption – a randomized double‐blind placebo‐controlled study in active Crohn’s disease
Steed, H., Macfarlane, G. T., Blackett, K. L., Bahrami, B., Reynolds, N., Walsh, S., Cummings, J. H., & Macfarlane, S. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04417.x · Cited by 256
Pouchitis: result of microbial imbalance?
Embden, J. G. R.-V., Schouten, W. R., & van Lieshout, L. M. (1994) · Gut · doi:10.1136/gut.35.5.658 · Cited by 255
Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
Tursi, A., Brandimarte, G., Giorgetti, G. M., Forti, G., Modeo, M. E., & Gigliobianco, A. (2004) · PubMed · Cited by 241
Probiotics in the Management of Inflammatory Bowel Disease: A Systematic Review of Intervention Studies in Adult Patients
Jonkers, D., Penders, J., Masclee, A., & Pierik, M. (2012) · Drugs · doi:10.2165/11632710-000000000-00000 · Cited by 240
Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment
Ulisse, S., Gionchetti, P., D’Alò, S., Russo, F. P., Pesce, I., Ricci, G., Rizzello, F., Helwig, U., Cifone, M. G., Campieri, M., et al. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.04139.x · Cited by 214
Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)
Matthes, H., Krummenerl, T., Giensch, M., Wolff, C., & Schulze, J. (2010) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-10-13 · Cited by 207
Probiotics for induction of remission in Crohn's disease
Limketkai, B. N., Akobeng, A. K., Gordon, M. A., & Adepoju, A. A. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006634.pub3 · Cited by 205
Probiotics for maintenance of remission in ulcerative colitis
Iheozor‐Ejiofor, Z., Kaur, L., Gordon, M. A., Baines, P. A., Sinopoulou, V., & Akobeng, A. K. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007443.pub3 · Cited by 193
Probiotics and the Management of Inflammatory Bowel Disease
Fedorak, R. N., & Madsen, K. L. (2004) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200405000-00018 · Cited by 174
Probiotic Effects on Inflammatory Bowel Disease1,
Sheil, B., Shanahan, F., & O’Mahony, L. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.3.819s · Cited by 167
Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease
Seksik, P., Sokol, H., Lepage, P., Vasquez, N., Manichanh, C., Mangin, I., Pochart, P., Dore, J. M., & Marteau, P. R. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03053.x · Cited by 166
VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis
Dai, C., Zheng, C., Meng, F., Zhou, Z., Sang, L.-X., & Jiang, M. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1488-3 · Cited by 156
A comparative study of the preventative effects exerted by two probiotics,Lactobacillus reuteriandLactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis
Perán, L., Sierra, S., Comalada, M., Lara‐Villoslada, F., Bailón, E., Nieto, A., Concha, Á., Olivares, M. M., Zarzuelo, A., Xaus, J., et al. (2007) · British Journal Of Nutrition · doi:10.1017/s0007114507257770 · Cited by 155
Crohn's disease
Fellermann, K., Wehkamp, J., Herrlinger, K. R., & Stange, E. F. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200306000-00008 · Cited by 148
Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis
Ng, S. C., Plamondon, S., Kamm, M. A., Hart, A. L., Al-Hassi, H. O., Guenther, T., Stagg, A. J., & Knight, S. C. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21222 · Cited by 147
A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis
Wildt, S., Nordgaard, I., Hansen, U., Brockmann, E., & Rumessen, J. J. (2011) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2010.11.004 · Cited by 141
Lactobacillus plantarum strain YU from fermented foods activates Th1 and protective immune responses
Kawashima, T., Hayashi, K., Kosaka, A., Kawashima, M., Igarashi, T., Tsutsui, H., Tsuji, N. M., Nishimura, I., Hayashi, T., & Obata, A. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.08.013 · Cited by 124
Mucosal Immunology and Probiotics
Dongarrà, M. L., Rizzello, V., Muccio, L., Fries, W., Cascio, A., Bonaccorsi, I., & Ferlazzo, G. (2012) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0313-0 · Cited by 122
Probiotics in inflammatory bowel disease: possible mechanisms of action.
Dotan, I., & Rachmilewitz, D. (2005) · PubMed · Cited by 121
VSL#3 probiotics regulate the intestinal epithelial barrier inï¿½vivo and in vitro via the p38 and ERK signaling pathways
Jiang, M. (2011) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2011.839 · Cited by 119
Antibiotics and probiotics in treatment of inflammatory bowel disease
Gionchetti, P. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i21.3306 · Cited by 113
Regulation of intestinal homeostasis by innate and adaptive immunity
Kayama, H., & Takeda, K. (2012) · International Immunology · doi:10.1093/intimm/dxs094 · Cited by 107
Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate
Kumar, N. S. N., Ramadass, B., Jayakanthan, K., Pulimood, A. B., Pugazhendhi, S., & Ramakrishna, B. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05723.x · Cited by 102
Physiological Basis for Novel Drug Therapies Used to Treat the Inflammatory Bowel Diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease
Shanahan, F. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00421.2004 · Cited by 82
Bacteria in the pathogenesis of inflammatory bowel disease
Subramanian, S., Campbell, B. J., & Rhodes, J. M. (2006) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000244054.69253.f3 · Cited by 75
Stories of love and hate
Rosenstiel, P. C. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835da2c7 · Cited by 49
Anti-inflammatory potential of the probiotic dietary supplement Lactibiane Tolérance: In vitro and in vivo considerations
Drouault-Holowacz, S., Foligné, B., Dennin, V., Goudercourt, D., Terpend, K., Burckel, A., & Pot, B. (2006) · Clinical Nutrition · doi:10.1016/j.clnu.2006.03.006 · Cited by 30
Re.: Oral administration of a certain strain of liveEscherichia coli for intestinal disorders? (Infection 23 [1995] 51–54)
Schulze, J., & Sonnenborn, U. (1995) · Infection · doi:10.1007/bf01793863 · Cited by 24
Maintaining Remission of Ulcerative Colitis with the Probiotic Escherichia Coli Nissle 1917 is as Effective as with Standard Mesalazine
Adam, B., Liebregts, T., & Holtmann, G. (2006) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2005-858972 · Cited by 24
Probiotic Bacteria in the Prevention and the Treatment of Inflammatory Bowel Disease
Fedorak, R. N., & Demeria, D. D. (2012) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2012.08.003 · Cited by 24
Crohn's disease intestinal CD4+ T cells have impaired interleukin-10 production which is not restored by probiotic bacteria
Hvas, C. L., Kelsen, J., Agnholt, J. S., Höllsberg, P., Tvede, M., Møller, J. K., & Dahlerup, J. F. (2007) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520601013754 · Cited by 22
Therapy with E.coli nissle reduces concentrations of mucosa associated colonic flora in patients with ulcerative colitis
Swidsinski, A. V., Swidsinski, S., Godzun, A., Orthner, M., & Lochs, H. H. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)80362-5 · Cited by 5
Escherichia coli strain nissie 1917 inhibits adhesion to an invasion of intestinal epithelial cells by adherent-invasive E. colil isolated from a Crohn's disease patient
Boudeau, J., Rich, C., Colombel, J., & DARTEUILLEMICHAUD, A. (2001) · Gastroenterology · doi:10.1016/s0016-5085(08)80940-7 · Cited by 2
[Probiotics--should we change the treatment strategy for pouchitis?].
Klinge, L. G., & Kjeldsen, J. (2006) · PubMed · Cited by 2

Research works printed but not linked: 10

Dotan, 2005, Curr Opin Gastroenterol, 21, 426
Rutgeerts, 2007, 56, 453
Ruseler-van Embden, 1994, 35, 658
Klinge, 2006, 168, 3516
Butterworth, 2008, Cochrane Database Syst Rev, &NA;, CD006634
Malchow, 1997, A new approach in therapy to maintain remission of colonic Crohns disease J Clin Gastroenterol, 25, 653
Tursi, 2004, Med Sci Monit, 10, PI126
Dai, 2012, Int J Mol Med, 29, 202
Schulze, 1995, 23, 184
Fellermann, 2003, Crohns disease: a defensin deficiency syndrome Eur J Gastroenterol Hepatol, 15, 627

Sorted by citations

Influence of diet on the gut microbiome and implications for human health
Singh, R. K., Chang, H.-W., Yan, D., Lee, K. M., Ucmak, D., Wong, K., Abrouk, M., Farahnik, B., Nakamura, M., Zhu, T. H., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1175-y · Cited by 2,599
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
The gut microbiota and host health: a new clinical frontier
Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D. A., Hirschfield, G. M., Hold, G., Quraishi, M. N., Kinross, J., Smidt, H., Tuohy, K. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309990 · Cited by 2,302
“82”
Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management
Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., Kucharzik, T., Molnár, T., Raine, T., Sebastian, S., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx009 · Cited by 1,180
Gut Microbiome: Profound Implications for Diet and Disease
Hills, R. D., Pontefract, B., Mishcon, H. R., Black, C. A., Sutton, S. C., & Theberge, C. R. (2019) · Nutrients · doi:10.3390/nu11071613 · Cited by 1,143

See all 364

Authors: Shen, J., Zuo, Z.-X., & Mao, A.-P.
Affiliations: Shanghai Jiao Tong University (CN)
ORCID: Shen, Jun
Venue: Inflammatory Bowel Diseases
Publisher: Oxford University Press (OUP)
Published: 2014-01
Volume: 20
Issue: 1
Pages: 21-35
ISSN: 1078-0998 (ISSN-L)
DOI: 10.1097/01.mib.0000437495.30052.be
OpenAlex: W1997405434
Cited by: 364
References: 57
Citations by year: 2026: 4 · 2025: 13 · 2024: 16 · 2023: 18 · 2022: 22 · 2021: 26 · 2020: 74 · 2019: 18 · 2018: 33 · 2017: 46 · 2016: 38 · 2015: 34 · 2014: 22
FWCI: 3.85
Type: journal article
Language: en
Open access: closed
Locations: Inflammatory Bowel Diseases (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords: probiotics, ulcerative colitis
MeSH terms: Colitis, Ulcerative, Crohn Disease, Humans, Prognosis, Remission Induction, Randomized Controlled Trials as Topic, Pouchitis, Probiotics, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Probiotics on Inducing Remission and Maintaining Therapy in Ulcerative Colitis, Crohnʼs Disease, and Pouchitis: Meta-analysis of Randomized Controlled Trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks